ArticleBMC women's health2026
Investigation of the relationship between pentraxin 3 levels and pain in patients with primary dysmenorrhea.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary dysmenorrhea is a type of menstrual pain characterized by uterine-origin cramps in the suprapubic region without any underlying pelvic pathology. It is a chronic pain syndrome that negatively affects the quality of life of millions of women worldwide. Pentraxin-3 (PTX3) is a long-chain pentraxin, an acute-phase plasma protein that plays a role in both acute and chronic inflammation and innate immunity. In this study, the diagnostic biomarker value of serum PTX3 levels and the relationship between serum PTX3 and pain were investigated in patients diagnosed with primary dysmenorrhea. MATERIALS AND
methodsThis research included 50 patients who presented to the obstetrics and gynecology outpatient clinic and emergency department with complaints of primary dysmenorrhea between July 1, 2025, and September 1, 2025. Moreover, a control group of 50 healthy women, matched with the patient group and without primary dysmenorrhea, was included. PTX3 levels were measured via enzyme-linked immunosorbent assay (ELISA).
resultsMedian PTX3 levels in patients were significantly higher than controls (p < 0.001). PTX3 levels also increased significantly as pain intensity increased (p < 0.001). A significant, strong, and positive correlation was observed between visual analog scale (VAS) scores and PTX3 levels (r = 0.838, p < 0.001). When the cut-off value for PTX3 levels was set at 5.24 ng/ml, sensitivity was 81% and specificity was 95% (AUC = 0.918, p < 0.001).
conclusionIn primary dysmenorrhea, PTX3 levels increase with the severity of pain. PTX3 could be an important diagnostic biomarker of primary dysmenorrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.